Themed issue on cannabinoids in biology and medicine

British Journal of Pharmacology

Volumn 163, Issue 7, 2011, Pages 1327-1328

  Bab, Itai ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

cannabinoid receptors; cannabinoids; endocannabinoid metabolizing enzymes; endocannabinoids; Mechoulam

Indexed keywords

ACYLGLYCEROL LIPASE; ADENYLATE CYCLASE; ANANDAMIDE; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; DRONABINOL; LIPOPROTEIN LIPASE; PHOSPHOLIPASE D; PHYTOCANNABINOID; UNCLASSIFIED DRUG; CANNABINOID; CANNABIS; PSYCHEDELIC AGENT; TETRAHYDROCANNABINOL;

ANALGESIC ACTIVITY; BONE MASS; BRAIN DISEASE; CHRONIC PAIN; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; NEUROPATHIC PAIN; NEUROPROTECTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SPASTICITY; CANCER THERAPY; CHRONIC LIVER DISEASE; DRUG EFFECT; DRUG SAFETY; HUMAN; METABOLIC SYNDROME X;

ANIMALS; CANNABINOIDS; HUMANS;

EID: 79960325869     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01536.x     Document Type: Editorial

References (22)

1. Bab I, Smoum R, Bradshaw H, Mechoulam R, (2011). Skeletal lipidomics: regulation of bone metabolism by fatty acid amide family. Br J Pharmacol 163: 1441-1446.
2. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al,. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949. (Pubitemid 23026736)
3. Fernández-Ruiz J, Moreno-Martet M, Rodríguez-Cueto C, Palomo-Garo C, Gõmez-Cañas M, Valdeolivas S, et al,. (2011). Prospects for cannabinoid therapies in basal ganglia disorders. Br J Pharmacol 163: 1365-1378.
4. Gaoni Y, Mechoulam R, (1964). Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86: 1646-1647.
5. Guindon J, Hohmann AG, (2011). The endocannabinoid system and cancer: therapeutic implications. Br J Pharmacol 163: 1447-1463.
6. Howlett AC, (1985). Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Mol Pharmacol 27: 429-436. (Pubitemid 15088930)
7. Howlett AC, Reggio PH, Childers SR, Hampson RE, Ulloa NM, Deutsch DG, (2011). Endocannabinoid tone versus constitutive activity of cannabinoid receptors. Br J Pharmacol 163: 1329-1343.
8. 1 receptor blockade in the treatment of visceral obesity and its cardiometabolic complications. Br J Pharmacol 163: 1423-1431.
9. Ligresti A, Cascio MG, Di Marzo V, (2005). Endocannabinoid metabolic pathways and enzymes. Curr Drug Targets CNS Neurol Disord 4: 615-623. (Pubitemid 41782623)
10. Lynch ME, Campbell F, (2011). Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol DOI: 10.1111/j.1365-2125.2011.03970.x.
11. McKinney MK, Cravatt BF, (2005). Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 74: 411-432. (Pubitemid 40995513)
12. Maccarrone M, Bernardi G, Agrò AF, Centonze D, (2011). Cannabinoid receptor signalling in neurodegenerative diseases: a potential role for membrane fluidity disturbance. Br J Pharmacol 163: 1379-1390.
13. Mallat A, Teixeira-Clerc F, Deveaux V, Manin S, Lotersztajn S, (2011). The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings. Br J Pharmacol 163: 1432-1440.
14. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI, (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564.
15. 1-tetra- hydrocannabinol, the major active constituent of hashish. Tetrahedron Lett 12: 1109-1111.
16. 6-tetrahydrocannabinols. J Am Chem Soc 89: 4552-4554.
17. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al,. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83-90.
18. Munro S, Thomas KL, Abu-Shaar M, (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65. (Pubitemid 23305569)
19. Parker LA, Rock E, Limebeer C, (2011). Regulation of nausea and vomiting by cannabinoids. Br J Pharmacol 163: 1411-1422.
20. Russo EB, (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 163: 1344-1364.
21. Sarne Y, Asaf F, Fishbein M, Gafni M, Keren O, (2011). The dual neuroprotective-neurotoxic profile of cannabinoid drugs. Br J Pharmacol 163: 1391-1401.
22. Shohami E, Cohen-Yeshurun A, Magid L, Elgali M, Mechoulam R, (2011). Endocannabinoids and traumatic brain injury. Br J Pharmacol 163: 1402-1410.